Macrophage activation is associated with poorer long-term outcomes in renal transplant patients

Clinical Transplantation

Volumn 25, Issue 5, 2011, Pages 744-754

  Grebe, Scott O ^a   Kuhlmann, Uwe ^b   Fogl, Dominik ^c   Luyckx, Valerie A ^d   Mueller, Thomas F ^d  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute phase response; Cardiovascular disease; Kidney graft outcome; Macrophages; Neopterin; Patient survival

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; NEOPTERIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; DIALYSIS; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DEATH; HUMAN; KIDNEY TRANSPLANTATION; LONG TERM CARE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL RISK; SURVIVAL RATE; TREATMENT OUTCOME;

ACUTE-PHASE REACTION; ADULT; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; NEOPTERIN; PROGNOSIS; PROSPECTIVE STUDIES; SERUM AMYLOID A PROTEIN; SURVIVAL RATE;

EID: 80054104662     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01345.x     Document Type: Article

References (54)

1. Jevnikar AM, Mannon RB. Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol 2008: 3(Suppl. 2): S56.
2. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004: 4: 1289.
3. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000: 57: 307.
4. Dimeny EM. Cardiovascular disease after renal transplantation. Kidney Int Suppl 2002: 80: 78.
5. Gill JS. Cardiovascular disease in transplant recipients: current and future treatment strategies. Clin J Am Soc Nephrol 2008: 3(Suppl. 2): S29.
6. Pham PT, Pham PC, Danovitch GM. Cardiovascular disease posttransplant. Semin Nephrol 2007: 27: 430.
7. Schlondorff DO. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int 2008: 74: 860.
8. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005: 5: 2464.
9. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008: 359: 2195.
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005: 352: 1685.
11. Eardley KS, Kubal C, Zehnder D et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008: 74: 495.
12. Delanghe JR, Langlois MR, De Bacquer D et al. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis 2002: 160: 471.
13. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 2006: 8: 421.
14. Eisenberg MS, Chen HJ, Warshofsky MK et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000: 102: 2100.
15. Cueto-Manzano AM, Morales-Buenrostro LE, Gonzalez-Espinoza L et al. Markers of inflammation before and after renal transplantation. Transplantation 2005: 80: 47.
16. Fink JC, Onuigbo MA, Blahut SA et al. Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. Am J Kidney Dis 2002: 39: 1096.
17. Kruger B, Boger CA, Schroppel B et al. No effect of C-reactive protein (CRP) haplotypes on CRP levels and post-transplant morbidity and mortality in renal transplantation. Transpl Int 2008: 21: 452.
18. Perez RV, Brown DJ, Katznelson SA et al. Pretransplant systemic inflammation and acute rejection after renal transplantation. Transplantation 2000: 69: 869.
19. Van Ree RM, Oterdoom LH, De Vries AP et al. Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients. Nephrol Dial Transplant 2007: 22: 246.
20. Winkelmayer WC, Lorenz M, Kramar R, Fodinger M, Horl WH, Sunder-Plassmann G. C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant 2004: 4: 1148.
21. Pepys MB. C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol 2008: 4: 234.
22. Grebe SO, Mueller TF. Immune monitoring in organ transplantation using neopterin. Curr Drug Metab 2002: 3: 189.
23. Ray KK, Morrow DA, Sabatine MS et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007: 115: 3071.
24. Reibnegger G, Aichberger C, Fuchs D et al. Posttransplant neopterin excretion in renal allograft recipients - a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation 1991: 52: 58.
25. Srinivas TR, Kubilis PS, Croker BP. Macrophage index predicts short-term renal allograft function and graft survival. Transpl Int 2004: 17: 195.
26. Weimer R, Susal C, Yildiz S et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006: 6: 1865.
27. Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ et al. Elevated serum neopterin levels and adverse cardiac events at 6months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis 2008: 201: 176.
28. Teppo AM, Tornroth T, Honkanen E, Gronhagen-Riska C. Elevated serum C-reactive protein associates with deterioration of renal function in transplant recipients. Clin Nephrol 2003: 60: 248.
29. Varagunam M, Finney H, Trevitt R et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis 2004: 43: 502.
30. Park W, Griffin M, Grande JP, Cosio F, Stegall MD. Molecular evidence of injury and inflammation in normal and fibrotic renal allografts one year posttransplant. Transplantation 2007: 83: 1466.
31. Schnuelle P, Gottmann U, Koppel H et al. Comparison of early renal function parameters for the prediction of 5-year graft survival after kidney transplantation. Nephrol Dial Transplant 2007: 22: 235.
32. Mueller TF. Immunological Monitoring Following Organ Transplantation. Lengerich, Berlin, Duesseldorf: Pabst Science, 1999.
33. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002: 3: 175.
34. Schroecksnadel K, Frick B, Winkler C, Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006: 4: 205.
35. Weiss G, Willeit J, Kiechl S et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994: 106: 263.
36. Cirillo P, Pacileo M, De Rosa S et al. Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. J Thromb Haemost 2006: 4: 2248.
37. Fuchs D, Stahl-Hennig C, Gruber A, Murr C, Hunsmann G, Wachter H. Neopterin - its clinical use in urinalysis. Kidney Int Suppl 1994: 47: S8.
38. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008: 454: 428.
39. Erwig LP. Macrophages and hypoxia in human chronic kidney disease. Kidney Int 2008: 74: 405.
40. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008: 8: 958.
41. Wilson HM, Walbaum D, Rees AJ. Macrophages and the kidney. Curr Opin Nephrol Hypertens 2004: 13: 285.
42. Croker BP, Clapp WL, Abu Shamat AR, Kone BC, Peterson JC. Macrophages and chronic renal allograft nephropathy. Kidney Int Suppl 1996: 57: S42.
43. Labarrere CA, Lee JB, Nelson DR, Al-Hassani M, Miller SJ, Pitts DE. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 2002: 360: 1462.
44. Sezer S, Ozdemir FN, Arat Z, Turan M, Haberal M. Triad of malnutrition, inflammation, and atherosclerosis in hemodialysis patients. Nephron 2002: 91: 456.
45. Werner ER, Bichler A, Daxenbichler G et al. Determination of neopterin in serum and urine. Clin Chem 1987: 33: 62.
46. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004: 37: 684.
47. Wachter H. Neopterin: Biochemistry, Methods, Clinical Application. Berlin: Walter de Gruyter, 1991.
48. Nikolich-Zugich J. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol 2008: 8: 512.
49. Jungraithmayr TC, Reschke M, Grebe SO, Lange H, Radsak K, Mueller TF. Assessment of cytomegalovirus infections using neopterin and a new immunoblot. Clin Chim Acta 2001: 310: 63.
50. Muller TF, Gicklhorn D, Jungraithmayr T et al. Pattern and persistence of the epitope-specific IgM response against human cytomegalovirus in renal transplant patients. J Clin Virol 2002: 24: 45.
51. Betjes MG, Huisman M, Weimar W, Litjens NH. Expansion of cytolytic CD4+ CD28- T cells in end-stage renal disease. Kidney Int 2008: 74: 760.
52. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006: 1: 297.
53. Soderberg-Naucler C. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 2008: 41: 218.
54. Neurauter G, Wirleitner B, Laich A, Schennach H, Weiss G, Fuchs D. Atorvastatin suppresses interferon-gamma-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol 2003: 131: 264.